logo
Plus   Neg
Share
Email

Deere & Co Q4 Profit Rises - Quick Facts

Deere & Co. (DE) reported that its net income for the fourth quarter ended November 1, 2020 rose to $757 million or $2.39 per share, from $722 million or $2.27 per share last year. Analysts polled by Thomson Reuters expected the company to report earnings of $1.49 per share for the quarter. Analysts' estimates typically exclude special items.

Net income in the fourth quarter 2020 was negatively affected by impairment charges and employee-separation costs of $211 million. For the same period in 2019, the similar charges were $74 million.

In addition, net income was unfavorably affected by discrete adjustments to the provision for income taxes in both periods of 2020 and favorably impacted in both periods of 2019.

Worldwide net sales and revenues decreased 2 percent to $9.731 billion from last year. Analysts expected revenues of $7.68 billion for the quarter.

Looking ahead for for fiscal 2021, the company expects net income attributable to the company to be in a range of $3.6 billion to $4.0 billion.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
J&J Distributing has recalled various food products citing potential contamination with Listeria monocytogenes or Lm, an organism that can cause serious and sometimes fatal infections. According to the U.S. Department of Agriculture's Food Safety and Inspection Service or FSIS, around 33 pounds of ready-to-eat meat and poultry salads and wrap products have been called back. The U.S. Food and Drug Administration on Saturday authorized Johnson & Johnson's (JNJ) single-dose COVID-19 vaccine for emergency use. It is the first single-shot COVID-19 vaccine and the third COVID-19 vaccine for emergency use in the U.S. - the other two being Pfizer/BioNTech's BNT162b2 and Moderna's mRNA-1273. The U.S. Food and Drug Administration said that it will rapidly work toward finalization and issuance of an emergency use authorization of Johnson & Johnson's (JNJ) single-shot COVID-19 vaccine candidate.
Follow RTT